Understanding Atrasentan (Vanrafia) for IgA Nephropathy, with Richard Lafayette, MD

Just a few years ago, there were no US Food and Drug Administration-approved treatments for IgA nephropathy (IgAN), leaving nephrologists with limited options to offer their patients. Now, with a growing understanding of the disease’s pathogenesis and progression, a wave of targeted treatments has transformed the landscape, ushering in a new era of disease-specific care. Most recently, the FDA granted accelerated approval to Novartis’ atrasentan (Vanrafia), a once-daily, non-steroidal, oral treatment, for reducing proteinuria in adults with primary IgAN at risk of rapid disease progression based on a prespecified interim analysis of 36-week data from the ongoing phase 3 ALIGN trial. Of note, the decision marked the FDA’s first approval for a selective endothelin A receptor antagonist for reducing proteinuria in IgAN. In this interview with HCPLive, Richard Lafayette, MD, a professor of medicine and director of the Glomerular Disease Center at Stanford University Medical Center, explains ongoing unmet needs in IgAN care despite the availability of several new therapies and what benefit atrasentan may offer Full interview: https://www.hcplive.com/view/understa... Atrasentan approval: https://www.hcplive.com/view/atrasent... #Nephrology #IgAN #IgANephropathy #Kidney #Medicine